Risk of Postoperative Infectious Complications From Medical Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Adrenal Cortex Hormones
/ adverse effects
Digestive System Surgical Procedures
/ adverse effects
Humans
Immunologic Factors
/ adverse effects
Infections
/ chemically induced
Inflammatory Bowel Diseases
/ drug therapy
Integrins
/ antagonists & inhibitors
Mesalamine
/ adverse effects
Odds Ratio
Perioperative Period
Postoperative Complications
/ chemically induced
Prospective Studies
Retrospective Studies
Risk Factors
Tumor Necrosis Factor Inhibitors
/ adverse effects
biologic
infection
inflammatory bowel disease
postoperative
Journal
Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162
Informations de publication
Date de publication:
19 11 2020
19 11 2020
Historique:
received:
16
08
2019
pubmed:
13
2
2020
medline:
27
10
2021
entrez:
13
2
2020
Statut:
ppublish
Résumé
To assess the impact of inflammatory bowel disease (IBD) medications on postoperative infection risk within 30 days of surgery. We searched multiple electronic databases and reference lists of articles dating up to August 2018 for prospective and retrospective studies comparing postoperative infection risk in patients treated with an IBD medication perioperatively with the risk in patients who were not taking that medication. Outcomes were overall infectious complications and intra-abdominal infections within 30 days of surgery. Sixty-three studies were included. Overall infectious complications were increased in patients who received anti-tumor necrosis factor (TNF) agents (odds ratio [OR] 1.26; 95% confidence interval [CI], 1.07-1.50) and corticosteroids (OR 1.34; 95% CI, 1.25-1.44) and decreased in those who received 5-aminosalicylic acid (OR 0.63; 95% CI, 0.46-0.87). No difference was observed in those treated with immunomodulators (OR 1.08; 95% CI, 0.94-1.25) or anti-integrin agents (OR 1.06; 95% CI, 0.67-1.69). Both corticosteroids and anti-TNF agents were associated with increased intra-abdominal infection risk (OR 1.63; 95% CI, 1.33-2.00 and OR 1.46; 95% CI, 1.08-1.97, respectively), whereas no impact was observed with 5-aminosalicylates, immunomodulators, or anti-integrin therapy. Twenty-two studies had low risk of bias while the remaining studies had very high risk. Corticosteroids and anti-TNF agents were associated with increased overall postoperative infection risk as well as intra-abdominal infection in IBD patients, whereas no increased risk was observed for immunomodulators or anti-integrin therapy. Although these results may result from residual confounding rather than from a true biological effect, prospective studies that control for potential confounding factors are required to generate higher-quality evidence.
Identifiants
pubmed: 32047894
pii: 5734556
doi: 10.1093/ibd/izaa020
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunologic Factors
0
Integrins
0
Tumor Necrosis Factor Inhibitors
0
Mesalamine
4Q81I59GXC
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1796-1807Informations de copyright
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.